Omeros (NASDAQ:OMER) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Omeros (NASDAQ:OMER – Get Rating) in a research report report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, UBS Group lowered shares of Omeros from a buy rating to a neutral rating in a research report on Thursday, December 8th.

Omeros Stock Down 9.9 %

Shares of OMER stock opened at $3.54 on Thursday. The firm has a market cap of $222.42 million, a PE ratio of 4.72 and a beta of 1.02. Omeros has a 12 month low of $1.74 and a 12 month high of $7.75. The stock has a 50 day moving average of $3.61 and a 200-day moving average of $3.28. The company has a quick ratio of 7.30, a current ratio of 3.25 and a debt-to-equity ratio of 2.58.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Omeros by 0.4% during the first quarter. BlackRock Inc. now owns 4,065,401 shares of the biopharmaceutical company’s stock worth $24,434,000 after buying an additional 15,373 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Omeros by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company’s stock valued at $20,642,000 after acquiring an additional 76,869 shares in the last quarter. State Street Corp increased its stake in Omeros by 2.8% in the first quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical company’s stock valued at $8,490,000 after acquiring an additional 38,498 shares during the period. Millennium Management LLC raised its position in Omeros by 188.1% in the second quarter. Millennium Management LLC now owns 1,220,782 shares of the biopharmaceutical company’s stock worth $3,357,000 after purchasing an additional 797,034 shares in the last quarter. Finally, UBS Group AG lifted its stake in Omeros by 23.9% during the second quarter. UBS Group AG now owns 674,780 shares of the biopharmaceutical company’s stock worth $1,856,000 after purchasing an additional 130,260 shares during the period. 32.64% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

(Get Rating)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.